Pashtoon M. Kasi

2 months ago | oncodaily.com | Pashtoon M. Kasi

Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope, shared a post on X:“Positive thing to look at ASCO each year is the “incremental” gains in survival for our patients with MSS colorectal cancer. A few years ago I started seeing survivals >40+ months. This year I’m seeing >50-52 months.

Aug 21, 2024 | onclive.com | Pashtoon M. Kasi

CommentaryPodcastAugust 21, 2024Author(s):Fact checked by:Drs Park and Kasi delve into the shift toward neoadjuvant immunotherapy and the use of ctDNA as a prognostic tool in colorectal cancer.

May 17, 2024 | onclive.com | Pashtoon M. Kasi

Pashtoon Murtaza Kasi, MD, MS, oncologist, researcher, Weill Cornell Medicine, NewYork-Presbyterian Hospital, discusses insights into and significant findings from the observational BESPOKE CRC study (NCT04264702) investigating circulating tumor DNA (ctDNA) and the study’s implications for clinical practice in treating patients with colorectal (CRC) cancer.

May 1, 2024 | medscape.com | Benjamin L. Schlechter |Pashtoon M. Kasi

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Benjamin L. Schlechter, MD: Hello. I'm Dr Benjamin Schlechter and welcome to Medscape's InDiscussion series on colorectal cancer. Today, we're discussing circulating tumor DNA (ctDNA) and colorectal cancer with Dr Pashtoon Kasi.

Apr 12, 2024 | onclive.com | Pashtoon M. Kasi

Pashtoon Murtaza Kasi, MD, MS, oncologist and researcher, Weill Cornell Medicine and NewYork-Presbyterian Hospital, discussess the propensity for over-treatment in the adjuvant setting across various cancers, including colorectal cancer (CRC), and the potential to use circulating tumor DNA (ctDNA) to inform treatment decision-making in this setting. He highlights the challenge of accurately discerning patients who are cured following surgery vs those who may require further aggressive therapy.